Cell Transplantation Combined with Recombinant Collagen Peptides for the Treatment of Fabry Disease

Daisuke Kami1, Masashi Yamanami2, Takahiro Tsukimura3, Hideki Maeda4, Tadayasu Togawa3, Hitoshi Sakuraba2, and Satoshi Gojo1

Abstract
Fabry disease is caused by a decrease in or loss of the activity of alpha-galactosidase, which causes its substrates globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso-Gb3) to accumulate in cells throughout the body. This accumulation results in progressive kidney injury due to glomerulosclerosis and in heart failure due to hypertrophy. Enzyme replacement therapy (ERT) has been used as the standard therapy for Fabry disease, but it causes a significant financial burden, and regular administration is inconvenient for patients. Because of the short half-life of alpha-galactosidase in vivo, therapeutic methods that can supplement or replace ERT are expected to involve continuous release of alpha-galactosidase, even at low doses. Cell transplantation therapy is one of these methods; however, its use has been hindered by the short-term survival of transplanted cells. CellSaic technology, which utilizes cell spheroids that form after cells are seeded simultaneously with a recombinant collagen peptide scaffold called a μ-piece, has been used to improve cell survival upon implantation. In this study, syngeneic murine embryonic fibroblasts were used to generate CellSaic that were transplanted into Fabry mice. These spheroids survived for 28 days in the renal subcapsular space with forming blood vessels. These results indicate CellSaic technology could be a platform to promote cellular graft survival and may facilitate the development of cell transplantation methods for lysosomal diseases.

Keywords
Fabry disease, alpha-galactosidase (GLA in humans and Gla in mice), globotriaosylceramide (Gb3), globotriaosylsphingosine (lyso-Gb3), cell transplantation, spheroid, CellSaic

Introduction
Fabry disease, considered a representative lysosomal disease, is a genetic disease caused by deficient enzymatic activity of alpha-galactosidase, which is encoded by the GLA gene on the X chromosome. Due to this deficiency, glycosphingolipids such as globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso-Gb3), which are substrates for alpha-galactosidase, progressively accumulate in intracellular lysosomes and body fluids. As a result, various clinical manifestations such as cardiomyopathy can occur, resulting in heart failure and renal failure, the latter of which requires hemodialysis or kidney transplantation and contributes to the short life expectancy of 58.2 years among males with Fabry disease1. At present, a standard treatment for Fabry disease is enzyme replacement therapy (ERT)2,3. Although ERT initiated in the early phase of cardiac4 or renal damage5 can effectively prevent disease progression, ERT cannot reverse pathophysiology in patients in whom either cardiac hypertrophy or reductions in glomerular filtration rate have already manifested. The economic burden...
and inconvenience of biweekly outpatient visits are disadvantages of ERT, and a novel therapeutic strategy is needed. Recently, the oral drug migalastat, which functions as a chaperone of specific mutant enzymes that are amenable to therapy, was found to demonstrate effects similar to those of intravenous ERT. Migalastat stabilizes a specific mutant form of an enzyme that is trafficked to lysosomes and hydrolyzes substances. It is estimated that 35%–50% of patients with Fabry disease have amenable mutations based on the Sakuraba database of Fabry disease (http://fabry-database.org/).

Physiologically, lysosomal enzymes to be ubiquitously expressed are cotranslationally glycosylated in the rough endoplasmic reticulum, acquire mannose-6-phosphate (M6P) in the cis-Golgi, and are sequentially entrapped by M6P receptors on budding vesicles from the trans-Golgi to the vesicle, resulting in the dissociation of M6P receptors following fusions with endosomes to generate acidic lysosomes where lysosomal enzymes function to hydrolyze their substrates. In the trans-Golgi, in part, oligosaccharides on lysosomal enzymes are remodeled with the removal of mannose and the supplementation of galactose and sialic acids instead of the phosphorylation of mannose, resulting in the secretion of the enzymes without M6P. On the other hand, M6P receptors on plasma membranes facilitate the internalization of extracellular lysosomal enzymes with M6P, which is the underpinning for ERT. Stem-cell-based cell and gene therapies for lysosomal diseases have been thoroughly investigated in animal models, and some clinical trials have been performed based on the assumption that transplanted cells could release lysosomal enzymes into the circulation. Although hematopoietic stem cell transplantation (HSC Tx) offers a successful outcome in terms of life expectancy for Hurler’s syndrome, which is the most severe form of type-I mucopolysaccharidosis (MPS I), other lysosomal diseases, such as type-II mucopolysaccharidosis (MPS II, Hunter syndrome), type-III mucopolysaccharidosis (MPS III, Sanfilippo syndrome), and Batten disease, do not respond to HSC Tx. Moreover, allogeneic HSC Tx requires myeloablative preconditioning, which is closely associated with perioperative mortality and morbidity. The discovery that alpha-galactosidase secreted from genetically modified cells into the circulation could release lysosomal enzymes into the circulation offers a successful outcome in terms of life expectancy for Fabry’s disease only. The survival and function of cellular grafts were assessed by pathology and the measurement of the amounts of lyso-Gb3, a biomarker of Fabry disease, in various organs.

**Materials and Methods**

**Animal Experiments**

All experiments were performed according to the animal experiment guidelines issued by the Animal Care and Use Committee at the Kyoto Prefectural University of Medicine and approved by the Animal Experiment Ethics Committee of the Kyoto Prefectural University of Medicine (approval number M2019-305).

**Cell Culture and CellSaic Stirring Culture**

Bone marrow-derived mesenchymal cells in Lewis rats were kindly provided from Jichi university. This cell line was cultured in minimum essential media supplemented with 10% fetal bovine serum (FBS) and 1% penicillin and streptomycin (Thermo Fisher Scientific Inc., Waltham, MA, USA). For MEF isolation, the uteri were removed from C57BL/6 mice that were 13.5 days pregnant and washed using phosphate-buffered saline (PBS) (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan). The head and visceral tissues were removed from the isolated embryos. Using two pregnant mice ranging between 18 and 20 days post-coitum, 1 to 5 x 10^7 cells could be acquired as primary fibroblasts to be used in further experiments. The remaining tissues were washed using fresh PBS, minced with scissors,
and transferred into fresh Dulbecco’s modified Eagle medium (DMEM; FUJIFILM Wako Pure Chemical Corporation) supplemented with 10% FBS and 1% penicillin and streptomycin (Thermo Fisher Scientific, Inc.). Three days after incubation, the outgrowth cells were trypsinized, collected by centrifugation (200 × g for 5 min), and resuspended in fresh medium. Following the first passage, 1 × 10⁶ cells were cultured in 150-mm dishes at 37°C in 5% CO₂. In this study, we used MEFs within 5–10 passages. The MEFs were cultured in DMEM containing 10% FBS and 1% penicillin and streptomycin at 37°C in 5% CO₂.

For CellSaic formation, rat bone marrow–derived mesenchymal cells (2 × 10⁶ per 100 μl of culture medium) were mixed with μ-pieces (FUJIFILM Wako Pure Chemical Corporation) and seeded onto a PrimeSurface® 96-well U-bottom plate (MS-9096U, Sumitomo Bakelite Co., Ltd, Tokyo, Japan) to determine the optimization of the contents of μ-pieces. For Mass production of CellSaics, 2-ml cell suspensions of MEFs at a density of 1 × 10⁶/ml with 1 mg/ml of μ-pieces were poured into an Elplasia multiple-pore hanging drop microplate, which is a six-well plate with an insert holding 468 pores (MPc500, Kuraray Co., Ltd, Tokyo, Japan). The CellSaic in the microplates was cultured and then transferred into a 30-ml stirred suspension bioreactor (BWV-S03A, Able Co., Tokyo, Japan) on day 2 after seeding, after which it was cultured on a six-channel magnetic stirrer (BWS-S03N05-6, Able Co.) at 37°C in 5% CO₂ for an additional 5–7 days.

Cell Transplantation Under the Renal Capsules

Under general anesthesia using isoflurane (1.5%) (v/v air; Mylan Inc., Tokyo, Japan), C57BL/6 mice were subjected to laparotomy, and the kidneys were exposed. Incisions were made horizontally in the renal capsules at the middle of the ventral aspect. CellSaic was transferred into the renal subcapsular spaces using sterilized tweezers under a stereomicroscope (Leica S6 E, Leica Microsystems GmbH, Wetzlar, Germany). The capsular incisions were closed by a few stiches with 7-0 proline, and the abdominal wounds were closed with two layers.

Tissue Preparation and Alpha-Galactosidase Activity Measurement

Mice were anesthetized and sacrificed 28 days after cell transplantation, and all tissues (liver, kidneys, and heart) were removed. The organs were assessed for alpha-galactosidase activity and Gb3 and lyso-Gb3 levels and were subjected to histological analysis. For determination of alpha-galactosidase activity, samples were homogenized in water and subjected to five freeze–thaw cycles using liquid nitrogen. The supernatant was collected after centrifugation of the homogenate at 10,000 × g for 5 min and was used for the enzyme assays. The protein concentration was measured with a BCA protein assay kit (Thermo Fisher Scientific Inc.) according to the manufacturer’s manual. Ten microliters of cell lysate at a concentration of 50 mg/ml was assayed with 20 μl of 4-methylumbelliferyl-alpha-D-galactopyranoside (2 mM, Sigma-Aldrich, Munich, Germany) in 0.06 M phosphate-citrate buffer (pH 4.7) (Merck KGaA, Darmstadt, Germany) according to a modified method from a previous report[1]. The enzyme reactions were terminated by the addition of 0.2 ml of 1.0 M glycine buffer (pH 10.5, adjusted with 1.0 M NaOH). The released 4-methylumbelliferone (4-MU) was assessed by fluorescence measurements at excitation and emission wavelengths of 360 and 465 nm, respectively, using a microplate fluorescence reader (Tecan Group Ltd, Männedorf, Switzerland). The measured enzyme activity was calculated as nmol 4-MU/mg protein or nmol 4-MU/h/ml. To measure the amounts of Gb3 and lyso-Gb3, we used ultra-performance liquid chromatography (UPLC)–tandem mass spectrometry (MS/MS) (UPLC: ACQUITY UPLC, Waters Corporation, Milford, MA, USA; MS/MS: Triple Quad5500, AB-Sciex Pty Ltd, Victoria, Australia) or an LCMS-8040 triple quadrupole mass spectrometer (Shimadzu Corporation, Kyoto, Japan) equipped with an electrospray ionization interface in positive-ion mode. Gb3, lyso-Gb3, and N,N-dimethyl-o-erythro-sphingosine were purchased from Matreya, LLC (Pleasant Gap, PA, USA) and used as internal standards (ISs) in these experiments. Briefly, mouse organs were collected, rapidly frozen in liquid nitrogen, and ground using a Multi-Beads Shocker MB8901CF (Yasui Kikai Co., Ltd, Osaka, Japan). The crushed samples were suspended by adding 10 times the weight of PBS. One hundred microliters of a methanol IS solution was added to 20 μl of mouse organ suspension. These mixtures were centrifuged to remove the protein, and the supernatant was diluted four-fold with 0.1% aqueous formic acid/50% methanol. The resulting samples were injected into the UPLC-MS/MS system. Quantitative analysis of lyso-Gb3 was performed with a TQD mass spectrometer coupled to an ACQUITY UPLC system equipped with an ACQUITY UPLC BEH Phenyl Column (130 Å, 1.7 μm, 2.1 mm × 50 mm; 186002885, Waters Corporation). Elution was performed with mobile phase A, which consisted of 0.1% formic acid and 1% acetonitrile in water, and mobile phase B, which consisted of 0.1% formic acid in methanol. Quantification of lyso-Gb3 was performed in multiple reaction monitoring mode. The targeted masses were an m/z of 786.336 for lyso-Gb3 and an m/z of 328.19 for lyso-Gb3-IS. The strongest peak derived from sphingosine was used for the determination. An m/z of 282.4 was used for lyso-Gb3, and an m/z of 110.0 was used for lyso-Gb3-IS. Gb3 and lyso-Gb3 levels were measured either per wet tissue weight or per protein weight.

Histology and Immunohistochemistry

Tissue samples were fixed with 4% paraformaldehyde (FUJIFILM Wako Pure Chemical Corporation) and embedded in paraffin. Hematoxylin and eosin (HE) staining was performed according to standard procedures. We performed morphological analysis of the grafts and the adjacent blood vessels in the HE-stained sections under light
microscopy. Apoptosis detection was performed using an Apoptag apoptosis detection kit (S7100, Merck Millipore, Billerica, MA, USA) for terminal deoxynucleotidyl transferase 2'-deoxyuridine 5'-triphosphate (dUTP) nick end labeling (TUNEL) according to the manufacturer’s instructions.

**Statistical Analysis**

The results are expressed as the means ± standard errors. The statistical significance of differences among groups was evaluated using t-tests and standard Bonferroni correction \( (P = 0.01) \) (Prism 8 software, GraphPad Prism Software Inc., San Diego, CA, USA), and \( P < 0.05 \) was considered to indicate significance.

**Results**

**Mass Production of CellSaic**

CellSaic technology is a new cell aggregation technology that uses recombinant peptide pieces called \( \mu \)-pieces for cell transplantation\(^{19} \). The mass of \( \mu \)-piece used to form CellSaic with rat bone marrow–derived mesenchymal cells was optimized by using PrimeSurface\(^ \circledast \) 96-well U-bottom plate (Fig. 1). In view of the uniform distribution of cells from the periphery to the center of CellSaics, a mass of \( \mu \)-pieces of 20 \( \mu \)g per CellSaic was chosen for further experiments. Large numbers of CellSaics are required for cell transplantation to modulate physiological functioning via the release of lysosomal enzymes from donor cells. Therefore, to facilitate the production of large numbers of CellSaics, we designed a CellSaic mass production system using a sphere-forming vessel and a stirring incubator (Fig. 2). Large numbers of CellSaics were produced by seeding 2 \( \times 10^6 \) MEFs plus 2 mg of \( \mu \)-pieces per well on Elplasia multiple-pore hanging drop microplates. The sphere-forming vessel requires only a one-time pouring of suspension solutions consisting of cells and \( \mu \)-pieces and drastically reduced the labor required to inject them several hundred times even by using a multipipette. The culture device limits the time necessary to provide compaction, which is known as the maturation process in spheroid culture, because of the restricted volume of the medium in which the spheroid is soaked. The CellSaics that were formed in a short duration in hanging drop culture were so fragile and did not fulfill the prerequisite that CellSaics have to be physiologically very rigid to tolerate a surgical transplantation procedure. Subsequent stirring culture in the spinner bottle for 5–7 days enabled compaction, which was observed as the downsizing of CellSaics (Fig. 3A). The process was designed as 2 days for hanging drop culture and 5 days for maturation culture; therefore, it took 7 days to complete the process to acquire CellSaic mass production. This production process could be easily expanded several hundred times in the number of CellSaics. From one 6-well plate, 3888 CellSaics containing 3 \( \times 10^3 \) cells could be acquired without labor-intensive work. Just after the formation of the spheroids, the histology of CellSaics showed uneven distribution of cells and \( \mu \)-pieces with sparse density in the center, whereas single-cell aggregates showed compact spheroids with rich density even in the center (Fig. 3B). After spheroids and CellSaic were cultivated for 1 week, they were histologically examined by counting TUNEL-positive cells in each mass had a diameter that ranged from a mean ± 2 standard errors. The TUNEL-positive ratio in spheroids was significantly higher than that in CellSaic (Supplemental Fig. 1). TUNEL staining revealed significant apoptotic cells in single-cell aggregates and almost no apoptotic cells in CellSaics (Fig. 3C). Histological examination following the whole process revealed that following maturation, the CellSaic possessed a uniform cell distribution regardless of the distance from the surface, whereas spheroids without \( \mu \)-pieces had centers devoid of cells that were surrounded by viable cell rims (Fig. 3C). The cell rims of the spheroids without \( \mu \)-pieces showed a gradual change from the periphery to the center. The outermost layer was composed of large cells, and the inner portion was formed by smaller cells, with a lower density in the center (Fig. 3C). To evaluate the apoptotic cells inside the cell aggregates with or without \( \mu \)-pieces, we used a TUNEL

**Figure 1.** Characteristics of CellSaics HE staining of cell spheres (without \( \mu \)-pieces) and CellSaics (with \( \mu \)-pieces) using rat bone marrow–derived mesenchymal cells. These cell structures were cultured in DMEM (10% FBS) for 2 days. The black bars indicate 50 \( \mu \)m. Cells without \( \mu \)-pieces (A) and with 5 \( \mu \)g/ml (B), 10 \( \mu \)g/ml (C), and 20 \( \mu \)g/ml (D) \( \mu \)-pieces. DMEM: Dulbecco’s modified Eagle medium; FBS: fetal bovine serum; HE: hematoxylin and eosin.
assay, a method for detecting apoptotic DNA fragmentation that is widely used to identify and quantify apoptotic cells (Fig. 3C). There were significant numbers of TUNEL-positive cells in the central parts of the spheroids without μ-pieces, whereas far fewer TUNEL-positive cells were found in the centers of the CellSaic structures. The size of the CellSaic structure that could be made by this method was 300–600 μm (78.4%) (Fig. 3D). The activities of alpha-galactosidase in 3D-cultured cells with and without μ-piece were significantly higher than that in 2D-cultured cells (Fig. 3E). The decreased alpha-galactosidase activity in CellSaic might be attributed to the protein content of the μ-piece. Next, alpha-galactosidase activities in 2 ml of the culture medium of CellSaics containing MEFs at a total cell number of 2 × 10^6 for 48 h were examined. Because the enzyme was contained in FBS, the activity of alpha-galactosidase to be released by MEFs in CellSaics was approximately 2 nmol/h/ml, which was calculated by subtracting the activity in the medium alone (Fig. 3F).

### Transplantation of CellSaic Containing Fibroblasts into Fabry Disease Model Mice

We examined the effects of CellSaic-containing MEFs on Fabry disease model mice that were generated by using CRISPR technology with a truncated enzyme at exon 3 (Supplemental Fig. 2). We examined the durability of spheroids and CellSaic under the renal capsule prior to the transplantation of CellSaic to Fabry mice on day 28. Spheroids showed central necrosis and an inflammatory reaction in the grafting site, whereas CellSaic maintained macroscopically visible cell clusters (Supplemental Fig. 3). Following the generation of CellSaics, 20 CellSaics were transplanted under the renal capsule in a kidney (Fig. 4A). By day 28 after transplantation into the renal subcapsular spaces, the grafts had generated viable masses, and newly formed blood vessels had entered the grafts. Numerous erythrocytes were observed inside the CellSaic structures (Fig. 4B). On day 28 after transplantation, there were few TUNEL-positive cells in the CellSaic structures. Moreover, on day 28, the amounts of lyso-Gb3 in the heart and the kidney did not significantly change (Supplemental Fig. 4), whereas the liver had significantly decreased in a dose-dependent manner (Fig. 4C). In preclinical studies of ERT for Fabry disease by using Fabry disease model mice, it was proven that recombinant alpha-galactosidase is primarily taken up by the liver. Although the Gb3 substrate was depleted in the liver at a single administration of 0.3 mg/kg, other tissues, including the heart, kidney, and spleen, did not show any significant changes. Following the administration of either agalsidase alfa or beta
to Fabry mice, the activities of alpha-galactosidase were one-order greater in the liver than in the heart or the kidney. Our results showed that the supply of alpha-galactosidase released from CellSaic affected only the liver that preferentially ingested the enzyme but was not enough to clear the storage substances in the heart and the kidney.

**Discussion**

This study demonstrates that CellSaic technology has significant potential to provide a platform for cell transplantation to treat lysosomal diseases. Fabry mice that received CellSaic-containing syngeneic MEFs showed not only long-term survival of grafted cells but also decreased lyso-Gb3 levels in the liver after 1 month. For clinical development using CellSaic technology, the mass production system was successfully developed in this study. In combination with CellSaic technology with gene modifications to release enough lysosomal enzymes enough to be taken up by defective cells and regain their function, CellSaics could offer an essential scaffold.
With respect to pharmacokinetics, steady release of the active enzyme from donor cells might be superior to biweekly administration of the recombinant lysosomal enzyme; this possibility has been supported by observations of improved substrate reduction resulting from HSC Tx relative to that achieved with ERT\textsuperscript{24}. The development of a cell transplantation strategy for lysosomal diseases has been hindered by the requirements of large numbers and long survival of cells that release lysosomal enzymes\textsuperscript{10}. Although many trials and studies have attempted to verify cell transplantation for the treatment of lysosomal diseases, including Fabry diseases, only bone marrow transplantation (BM Tx) and HSC Tx are recommended for patients suffering from MPS I diagnosed before the age of 2.5 years and clinically presumed Hurler syndrome\textsuperscript{13}. HSC Tx and BM Tx could result in relatively measurable comorbidity and perioperative mortality\textsuperscript{25}. In the case of alpha-galactosidase, the secreted enzyme does not seem to possess enough M6P moieties to be engulfed by other cells, as the absence of the cross-correction of cells with defective alpha-galactosidase activities was demonstrated by coculturing with wild-type cells\textsuperscript{26} and female patients who are heterozygotes for the allele of GLA exist\textsuperscript{27}. On the other hand, ex vivo gene therapy for Fabry disease using HSCs\textsuperscript{28} and mesenchymal stem cells\textsuperscript{29}, in which GLA is overexpressed, reported the correction of the deficiency in a murine model. The overexpression of alpha-galactosidase with M6P driven by an exogenous promoter might saturate the M6P receptors in the trans-Golgi to the fate to lysosomes and leak out of the cells; consequently, alpha-galactosidase might be effectively taken up in functioning lysosomes. Although the risk of provoking malignant transformation of transfected cells with the use of new recombinant lentiviruses is very low\textsuperscript{30}, it might not be negligible, especially for benign disorders with established and effective standard therapies such as Fabry disease.

We calculated cell numbers equivalent to ERT by using the measure of the enzyme activities in the culture medium of CellSaics containing MEFs. Agalsidase alfa has 2.1 mmol/h/protein mg of 4-MU-alpha-galactopyranoside-degrading activity\textsuperscript{21} and is administered twice weekly at a dose of 0.2 mg/kg to a patient. The pharmacokinetics showed urinary excretion of approximately 80% within the first 24 h, according to the manufacturer’s interview form. Given that the patient’s body weight is 60 kg, it is roughly calculated that 2.4 mg of the drug is taken up into body, resulting in 0.171 mg/day if simply divided by 14. Because the enzyme activity in the CellSaic medium is approximately 1 nmol/h/ml for 24 h (Fig. 3F), 0.171 mg enzyme protein corresponds to approximately 342 l of the culture medium. Because 2\textsuperscript{10} cells were contained in CellSaics for this 2 ml culture medium, 342 l of the culture medium corresponds to 171 \times 10\textsuperscript{9} cells, which requires approximately 86,000 wells holding 648 pores. Although alpha-galactosidase that is released from naïve cells does not possess M6P, it was reported that a lysosomal enzyme could be produced at several thousand–fold increase in transgenic mice compared with naïve mice and then released into the circulation\textsuperscript{31}, and 200 times more alpha-galactosidase activity was released from genetically modified fibroblasts in our laboratory, compared with the naïve cells (unpublished data). Two or more digit higher of enzyme release with M6P by gene-modified cells could be feasible, and work to address the number of cells and wells could be applicable to clinical fields.
In addition, the encapsulation of cells via either microencapsulation or macroencapsulation to support the release of biological materials such as insulin has been intensively investigated\textsuperscript{32,33}, but the strategy has not reached the clinical arena as a standard therapy mainly due to cellular durability. There have been no reports of the use of these technologies to treat lysosomal diseases. The CellSaic technology used in this study could possess the potential to resolve the main barrier of the cellular macroencapsulation strategy by promoting the survival and viability of grafted cells to be enclosed in the macroencapsulation device. Although this study lasted only 30 days, the results that the histopathological findings showed viable grafts without any apoptotic cells and the release of alpha-galactosidase also suggested that CellSaic technology could be suitable to embed graft cells for cell therapy for lysosomal diseases. We performed this experiment as a first step to a cell transplantation strategy to treat lysosomal diseases. One of the assumed final designs of the treatment could be a combination of CellSaic and macroencapsulation, which could escape from the host immune system, be metabolically maintained, and could release lysosomal enzymes. As there is substantial evidence that the macroencapsulation of islet cells could rescue diabetes mellitus in animal models, the methodology could work in the setting of lysosomal diseases.

The renal subcapsular space, which is easily vascularized by engrafted foreign tissues and shows advantages to prevent a risk of embolism by remnant of engrafted tissue over intravascular transplantation, was chosen for implantation of CellSaic-containing MEFs. As expected, vascular networks were formed in the CellSaic-implanted sites as early as 1 week following engrafting. Although the use of the renal subcapsular space provided proof of concept that CellSaic-containing fibroblasts can release alpha-galactosidase and decrease lyso-Gb3 levels in the liver, the site and the procedure used for implantation were not clinically relevant because of surgical risks and invasiveness. Although the subcutaneous space has similar characteristics as the renal subcapsular space, it is difficult to identify the implantation site after long periods, which is the reason for the choice of the renal subcapsular space. Conversely, with respect to the clinical situation, the subcutaneous space might be a potential site for CellSaic transplantation, especially due to the low invasiveness.

The results of this study reveal new possibilities in the field of cell therapy research beyond treatment with BM Tx or HSC Tx. Gene modifications could be the next step for clinical therapy along with donor cells to be chosen. Because molecular techniques for cellular genetic modification have been well developed, the use of CellSaic technology could be fruitful for the treatment of lysosomal diseases.

Acknowledgments
Dr Tsukasa Kitahashi and Dr Kentaro Nakamura, who are employees of FUJIFILM Corporation, provided technical support related to CellSaic.

Author Contributions
DK, HM, and SG designed the research and analyzed the data; DK and SG wrote the paper; MY, TTsu, and TTo performed the animal experiments; and HS reviewed and provided suggestions on the experiments and the manuscript.

Ethical Approval
This study was approved by the Animal Experiment Ethics Committee of the Kyoto Prefectural University of Medicine (Approval Number: M2019-305).

Statement of Human and Animal Rights
All of the experimental procedures involving animals were conducted in accordance with the animal experiment guidelines issued by the Animal Care and Use Committee at the Kyoto Prefectural University of Medicine.

Statement of Informed Consent
There are no human subjects in this article and informed consent is not applicable.

Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: SG and DK received a collaborative research grant from FUJIFILM Corporation. HS received research grants and personal fees from Sumitomo Dainippon Pharma Co., Ltd, and Sanofi Japan Co. outside of the submitted work. TTo received a research grant from Sanofi Japan Co. outside of the submitted work.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Funding was provided by a collaborative research grant from FUJIFILM Corporation.

ORCID iDs
Masashi Yamanami https://orcid.org/0000-0001-6862-8046
Satoshi Gojo https://orcid.org/0000-0001-8115-7816

Supplemental Material
Supplemental material for this article is available online.

References
1. Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P. Life expectancy and cause of death in males and females with Fabry disease: findings from the fabry registry. Genet Med. 2009;11(11):790–796.
2. El Dib R, Gomaa H, Carvalho RP, Camargo SE, Bazan R, Barretti P, Barreto FC. Enzyme replacement therapy for
anderson-fabry disease. Cochrane Database Syst Rev. 2016; 7(7):CD006663.

3. Rombach SM, Smid BE, Linthorst GE, Dijkstra MF, Hollak CE. Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages. J Inherit Metab Dis. 2014;37(3):341–352.

4. Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Stork S, Voelker W, Ertl G, Wanner C, Strotmann J. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation. 2009;119(4):524–529.

5. Germain DP, Charrow J, Desnick RJ, Guffon N, Kempf J, Lachmann RH, Lenay R, Linthorst GE, Packman S, Scott CR, Waldek S, et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet. 2015;52(5):353–358.

6. Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, Feliciani C, Shankar SP, Ezgu F, Amartino H, Bratkovic D, et al. Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat. N Engl J Med. 2016; 375(6):545–555.

7. Ramot Y, Steiner M, Morad V, Leibovitch S, Leibovitch S, Amouyal N, Cesta MF, Nyska A. Pulmonary thrombosis in the mouse following intravenous administration of quantum dot-labeled mesenchymal cells. Nanotoxicology. 2010;4(1):98–105.

8. Yam GH, Zuber C, Roth J. A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder. FASEB J. 2005;19(1):12–18.

9. Desnick RJ, Schuchman EH. Enzyme replacement and enhancement therapies: lessons from lysosomal disorders. Nat Rev Genet. 2002;3(12):954–966.

10. Kim SU. Lysosomal storage diseases: stem cell-based cell- and gene-therapy. Cell Transplant. 2014.

11. Boeens JJ, Wynn RF, O’Meara A, Veys P, Bertrand Y, Souillet G, Wraith JE, Fischer A, Cavazzana-Calvo M, Sykora KW, Selmä D, et al. Outcomes of hematopoietic stem cell transplantation for Hurler’s syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplant. 2007; 40(3):225–233.

12. Shihabuddin LS, Aubert I. Stem cell transplantation for neuro-degenerative diseases. Neuropharmacology. 2010;58(6):845–854.

13. Biffi A. Hematopoietic stem cell gene therapy for storage disease: current and New indications. Mol Ther. 2017;25(5):1155–1162.

14. Huang J, Khan A, Au BC, Barber DL, Lopez-Vasquez L, Prokopishyn NL, Bouterin M, Roth M, Rip JW, Abaoui M, Nagre MS, et al. Lentivector iterations and pre-clinical scale-up/toxicity testing: targeting mobilized cd34+ cells for correction of fabry disease. Mol Ther Methods Clin Dev. 2017; 5:241–258.

15. Nath S, Devi GR. Three-dimensional culture systems in cancer research: Focus on tumor spheroid model. Pharmacol Ther. 2016;163:94–108.

16. Pasca SP. The rise of three-dimensional human brain cultures. Nature. 2018;553(7689):437–445.

17. Itoh M, Mukae Y, Kitsuka T, Arai K, Nakamura A, Uchihashi K, Toda S, Matsubayashi K, Oyama J, Node K, Kami D, et al. Development of an immunodeficient pig model allowing long-term accommodation of artificial human vascular tubes. Nat Commun. 2019;10(1):2244.

18. Mueller-Klieser W. Multicellular spheroids. A review on cellular aggregates in cancer research. J Cancer Res Clin Oncol. 1987;113(2):101–122.

19. Nakamura K. CellSaic, a cell aggregate-like technology using recombinant peptide pieces for MSC transplantation. Curr Stem Cell Res Ther. 2019;14(1):52–56.

20. Nakamura K, lwazawa R, Yoshioka Y. Introduction to a new cell transplantation platform via recombinant peptide petaloid pieces and its application to islet transplantation with mesenchymal stem cells. Transpl Int. 2016;29(9):1039–1050.

21. Tajima Y, Kawashima I, Tsukimura T, Sugawara K, Kuroda M, Suzuki T, Togawa T, Chiba Y, Jigami Y, Ohno K, Fukushige T, et al. Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease. Am J Hum Genet. 2009;85(5):569–580.

22. Ioannou YA, Zeidner KM, Gordon RE, Desnick RJ. Fabry disease: preclinical studies demonstrate the effectiveness of α-galactosidase a replacement in enzyme-deficient mice. Am J Hum Genet. 2001;68(1):14–25.

23. Sakuraba H, Murata-Ohsawa M, Kawashima I, Tajima Y, Kotani M, Ohshima T, Chiba Y, Takashiba M, Jigami Y, Fukushige T. Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice. J Hum Genet. 2006;51(3):180–188.

24. Wynn RF, Wraith JE, Mercer J, O’Meara A, Tylee K, Thornley M, Church HJ, Bigger BW. Improved metabolic correction in patients with lysosomal storage disease treated with hematopoietic stem cell transplant compared with enzyme replacement therapy. J Pediatr. 2009;154(4):609–611.

25. de Ru MH, Boeens JJ, Das AM, Jones SA, van der Lee JH, Mahlaoui N, Mengel E, Offringa M, O’Meara A, Parini R, Rovelli A, et al. Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet J Rare Dis. 2011;6:55.

26. Fuller M, Mellett N, Hein LK, Brooks DA, Meikle PJ. Absence of alpha-galactosidase cross-correction in Fabry heterozygote cultured skin fibroblasts. Mol Genet Metab. 2015;114(2):268–273.

27. Beck M, Cox TM. Comment: why are females with Fabry disease affected? Mol Genet Metab Rep. 2019;21:100529.

28. Pacienza N, Yoshimitsu M, Mizue N, Au BC, Wang JC, Fan X, Takenaka T, Medin JA. Lentivector transduction improves outcomes over transplantation of human HSCs alone in NOD/SCID/Fabry mice. Mol Ther. 2012;20(7):1454–1461.
mesenchymal stem cells: efficacy study in a knock-out mouse model. Mol Ther. 2002;5(5):S15.
30. Milone MC, O’Doherty U. Clinical use of lentiviral vectors. Leukemia. 2018;32(7):1529–1541.
31. Vogler C, Galvin N, Levy B, Grubb J, Jiang H, Zhou XY, Sly WS. Transgene produces massive overexpression of human β-glucuronidase in mice, lysosomal storage of enzyme, and strain-dependent tumors. Proc Natl Acad Sci U S A. 2003;100(5):5.
32. Desai T, Shea LD. Advances in islet encapsulation technologies. Nat Rev Drug Discov. 2017;16(5):338–350.
33. Faleo G, Lee K, Nguyen V, Tang Q. Assessment of immune isolation of allogeneic mouse pancreatic progenitor cells by a macroencapsulation device. Transplantation. 2016;100(6):1211–1218.